STAT3 and non-Hodgkin lymphoma: Another example of inhibitors targeting Stat3 at different levels and currently used in clinical trials are: STAT3 antisense oligonucleotide (advanced stage/metastatic hepatocellular carcinoma) or STAT3 SH2 domain binder (multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukaemia, chronic myeloid leukaemia) [47].